share_log

Benchmark Reiterates Speculative Buy on Harvard Bioscience, Maintains $7 Price Target

Benzinga ·  Jun 22, 2023 08:24

Benchmark analyst Bruce Jackson reiterates Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment